ARIMOCLOMOL FOR TREATMENT OF GLUCOCEREBROSIDASE-ASSOCIATED DISORDERS Russian patent published in 2021 - IPC A61K31/4545 A61P25/16 A61P25/28 A61P43/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to the use of an active pharmaceutical ingredient selected from (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxymidoyl chloride and its acid-additive salts, for the treatment of glucocerebrosidase-associated (GBA) Parkinson's disease (PD) or GBA-associated parkinsonism, where said GBA-associated Parkinson's disease or parkinsonism is associated with reduced activity and/or levels of the GBA enzyme. The invention also relates to applications of an active pharmaceutical ingredient selected from (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxymidoyl chloride and its acid-additive salts.

EFFECT: proposed is the use of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)- propoxy]-pyridine-1-oxide-3-carboxymidoyl chloride and its acid-additive salts for the treatment of glucocerebrosidase-associated (GBA) Parkinson's disease (PD) or GBA-associated parkinsonism, which are associated with reduced activity and/or levels of the GBA enzyme.

33 cl, 20 dwg, 11 ex